US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Polyrizon Ltd.

12.85

+0.41503.34%

Post-market: 13.460.6150+4.79%19:32 EST

Volume:68.00K

Turnover:870.83K

Market Cap:13.38M

PE:-18.05

High:13.67

Open:12.52

Low:12.27

Close:12.43

52wk High:2,235.00

52wk Low:2.88

Shares:1.04M

Float Shares:996.80K

Volume Ratio:0.52

T/O Rate:6.82%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.7114

ROE:-12.20%

ROA:-22.25%

PB:0.73

PE(LYR):- -

Loading ...

Overview Company News Filings

BUZZ-U.S. STOCKS ON THE MOVE-SpyGlass, Agomab, Piper Sandler, Molina

BUZZ-U.S. STOCKS ON THE MOVE-Microchip, Under Armour, Avery Dennison

BRIEF-Clearmind Medicine Enters Development Agreement For Intranasal Formulation Of Proprietary Nonhallucinogenic Neuroplastogen MEAI

BUZZ-Polyrizon jumps as it teams up with Clearmind for intranasal drug delivery

Clearmind Medicine Enters Into Development Agreement to Advance Intranasal Formulation for Its Proprietary Non-Hallucinogenic Neuroplastogen Meai

THOMSON REUTERS

Polyrizon Partners with Clearmind to Develop Intranasal MEAI Formulation

Polyrizon Signs an Agreement to Develop Intranasal Proprietary Non-Hallucinogenic Neuroplastogen Formulation

THOMSON REUTERS

Polyrizon intends to acquire 51% stake in Arrow Aviation for NIS 18M

Polyrizon to Acquire 51% Stake in Arrow Aviation

Polyrizon Ltd - to Buy 51% Stake in Arrow Aviation for $5.8 Mln

THOMSON REUTERS

Polyrizon initiates key usability study program for NASARIX

Polyrizon Advances Regulatory Path With Initiation of Usability Study Program for Nasarix™ Allergy Blocker

THOMSON REUTERS

Polyrizon announces board authorized exploration of investment opportunities

BRIEF-Polyrizon Ltd To Explore Revenue-Generating Investment Opportunities In High-Growth Sectors

Polyrizon Ltd: Board Has Approved Pursing Selective Investments That Are Expected to Generate Near-Term Revenues

THOMSON REUTERS

Polyrizon - Focusing Its Initial Efforts on Operating Companies in High-Potential Sectors, Including Defense, Aviation, and AI

THOMSON REUTERS

Polyrizon Ltd: to Explore Revenue-Generating Investment Opportunities in High-Growth Sectors

THOMSON REUTERS

Polyrizon Ltd. Announces Plans to Explore Revenue-Generating Investments in Defense, Aviation, and AI Sectors While Advancing Core Intranasal Medical Pipeline

BRIEF-Polyrizon Expects Nasarix Introduction Aligned With Clinical Progress

Polyrizon's PL-14 Outperforms Standard Nasal Barrier in Blocking Allergens

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/PLRZ/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"PLRZ","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PLRZ\",,,,,undefined,":{"symbol":"PLRZ","market":"US","secType":"STK","nameCN":"Polyrizon Ltd.","latestPrice":12.845,"timestamp":1770411600000,"preClose":12.43,"halted":0,"volume":67997,"hourTrading":{"tag":"盘后","latestPrice":13.46,"preClose":12.845,"latestTime":"19:32 EST","volume":858,"amount":11310.614,"timestamp":1770424357562,"change":0.615,"changeRate":0.047879,"amplitude":0.069109},"delay":0,"changeRate":0.03338696701528567,"floatShares":996800,"shares":1041700,"eps":-0.71144193,"marketStatus":"Market Closed","change":0.415,"latestTime":"02-06 16:00:00 EST","open":12.52,"high":13.67,"low":12.27,"amount":870834.587132,"amplitude":0.112631,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-0.71144193,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1770627600000},"marketStatusCode":7,"adr":0,"listingDate":1730174400000,"exchange":"NASDAQ","adjPreClose":12.43,"preHourTrading":{"tag":"盘前","latestPrice":12.75,"preClose":12.43,"latestTime":"09:28 EST","volume":2261,"amount":28972.573833,"timestamp":1770388129016,"change":0.32,"changeRate":0.025744,"amplitude":0.099735},"postHourTrading":{"tag":"盘后","latestPrice":13.46,"preClose":12.845,"latestTime":"19:32 EST","volume":858,"amount":11310.614,"timestamp":1770424357562,"change":0.615,"changeRate":0.047879,"amplitude":0.069109},"volumeRatio":0.5165649948253132},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PLRZ\",,,,,undefined,":{"symbol":"PLRZ","floatShares":996800,"roa":"-22.25%","roe":"-12.20%","lyrEps":0,"volumeRatio":0.5165649948253132,"shares":1041700,"dividePrice":0,"high":13.67,"amplitude":0.112631,"preClose":12.43,"low":12.27,"week52Low":2.88,"pbRate":"0.73","week52High":2235,"institutionHeld":0,"latestPrice":12.845,"eps":-0.71144193,"divideRate":0,"volume":67997,"delay":0,"ttmEps":-0.71144193,"open":12.52,"prevYearClose":8.49,"prevWeekClose":11.51,"prevMonthClose":11.51,"prevQuarterClose":8.49,"fiveDayClose":11.51,"twentyDayClose":13.41,"sixtyDayClose":5.2416},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PLRZ\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-28","symbol":"PLRZ","defaultRemindTime":1764340200000,"type":"split","dateTimestamp":1764306000000,"forFactor":6,"toFactor":1,"ratio":6},{"market":"US","date":"2025-05-27","symbol":"PLRZ","defaultRemindTime":1748352600000,"type":"split","dateTimestamp":1748318400000,"forFactor":250,"toFactor":1,"ratio":250}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PLRZ\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PLRZ\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/PLRZ\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"PLRZ","date":"2026-02-06","current":-18.054882,"percent":0.107256,"low":-29.515607,"twenty":-11.383325,"median":-5.167341,"eighty":-1.959036,"high":-0.011381,"avg":-7.11177,"sd":6.228146,"marketCap":19812748},"quantilePoints":[{"date":"2024-10-31","current":-13.097935,"twenty":-22.948538,"median":-13.097935,"eighty":-12.489816,"marketCap":7858761},{"date":"2024-11-08","current":-3.903419,"twenty":-12.692522,"median":-4.690878,"eighty":-4.316449,"marketCap":3891709},{"date":"2024-11-15","current":-2.661127,"twenty":-9.219549,"median":-4.249136,"eighty":-3.530862,"marketCap":2653144},{"date":"2024-11-22","current":-2.985655,"twenty":-4.737156,"median":-3.736612,"eighty":-3.09924,"marketCap":2976698},{"date":"2024-11-29","current":-3.042447,"twenty":-4.451075,"median":-3.375089,"eighty":-3.037515,"marketCap":3033320},{"date":"2024-12-06","current":-3.212824,"twenty":-4.383762,"median":-3.342636,"eighty":-3.042447,"marketCap":3203186},{"date":"2024-12-13","current":-3.375088,"twenty":-4.191157,"median":-3.358862,"eighty":-3.047315,"marketCap":3364963},{"date":"2024-12-20","current":-7.561496,"twenty":-4.383762,"median":-3.375088,"eighty":-3.07146,"marketCap":7538812},{"date":"2024-12-27","current":-5.744141,"twenty":-5.095085,"median":-3.407542,"eighty":-3.090153,"marketCap":5726909},{"date":"2025-01-03","current":-5.938858,"twenty":-6.101122,"median":-3.569805,"eighty":-3.132991,"marketCap":5921041},{"date":"2025-01-10","current":-4.997727,"twenty":-6.159537,"median":-3.796975,"eighty":-3.146231,"marketCap":4982734},{"date":"2025-01-17","current":-6.142316,"twenty":-6.098128,"median":-3.933764,"eighty":-3.167391,"marketCap":6123889},{"date":"2025-01-24","current":-5.889893,"twenty":-6.192801,"median":-4.333277,"eighty":-3.193353,"marketCap":5872223},{"date":"2025-01-31","current":-5.553327,"twenty":-6.125488,"median":-4.527162,"eighty":-3.214122,"marketCap":5536667},{"date":"2025-02-07","current":-4.552045,"twenty":-6.087615,"median":-4.738105,"eighty":-3.227753,"marketCap":4538389},{"date":"2025-02-14","current":-4.711914,"twenty":-6.064471,"median":-4.705652,"eighty":-3.245278,"marketCap":4697778},{"date":"2025-02-21","current":-4.522596,"twenty":-6.049761,"median":-4.627772,"eighty":-3.258259,"marketCap":4509028},{"date":"2025-02-28","current":-3.707687,"twenty":-6.000655,"median":-4.535397,"eighty":-3.316674,"marketCap":3696564},{"date":"2025-03-07","current":-3.460732,"twenty":-5.929065,"median":-4.501561,"eighty":-3.241954,"marketCap":3450350},{"date":"2025-03-14","current":-1.846098,"twenty":-5.873065,"median":-4.396383,"eighty":-3.213473,"marketCap":2852222},{"date":"2025-03-21","current":-1.508371,"twenty":-5.793429,"median":-4.291207,"eighty":-3.160314,"marketCap":2330433},{"date":"2025-03-28","current":-1.353625,"twenty":-5.705978,"median":-3.977976,"eighty":-3.07146,"marketCap":2091350},{"date":"2025-04-04","current":-0.974631,"twenty":-5.536499,"median":-3.903419,"eighty":-3.030526,"marketCap":1505805},{"date":"2025-04-11","current":-0.980061,"twenty":-5.4398,"median":-3.702849,"eighty":-2.640357,"marketCap":1514194},{"date":"2025-04-17","current":-0.985491,"twenty":-5.322255,"median":-3.619184,"eighty":-1.846098,"marketCap":1522583},{"date":"2025-04-25","current":-0.947483,"twenty":-5.174691,"median":-3.5049,"eighty":-1.520317,"marketCap":1463861},{"date":"2025-05-02","current":-0.687943,"twenty":-5.159991,"median":-3.434137,"eighty":-1.353625,"marketCap":1062872},{"date":"2025-05-09","current":-2.602277,"twenty":-5.095085,"median":-3.375088,"eighty":-1.466019,"marketCap":4020518},{"date":"2025-05-16","current":-0.039201,"twenty":-5.02132,"median":-3.354145,"eighty":-1.299871,"marketCap":60566},{"date":"2025-05-23","current":-0.018499,"twenty":-5.006408,"median":-3.310183,"eighty":-1.057434,"marketCap":28581},{"date":"2025-05-30","current":-0.022023,"twenty":-4.999463,"median":-3.245278,"eighty":-1.021327,"marketCap":34025},{"date":"2025-06-06","current":-0.014912,"twenty":-4.937359,"median":-3.214447,"eighty":-0.978975,"marketCap":23039},{"date":"2025-06-13","current":-0.018851,"twenty":-4.922267,"median":-3.183486,"eighty":-0.945854,"marketCap":29125},{"date":"2025-06-20","current":-0.013358,"twenty":-4.871782,"median":-3.155299,"eighty":-0.895899,"marketCap":20638},{"date":"2025-06-27","current":-2.431375,"twenty":-4.817057,"median":-3.116926,"eighty":-0.895899,"marketCap":3756474},{"date":"2025-07-03","current":-2.428961,"twenty":-4.79003,"median":-3.054617,"eighty":-0.90676,"marketCap":3752744},{"date":"2025-07-11","current":-2.469311,"twenty":-4.75787,"median":-3.036282,"eighty":-0.929565,"marketCap":3815085},{"date":"2025-07-18","current":-3.343916,"twenty":-4.728069,"median":-3.039365,"eighty":-0.942596,"marketCap":5166350},{"date":"2025-07-25","current":-4.793774,"twenty":-4.784488,"median":-3.066787,"eighty":-0.954976,"marketCap":7406381},{"date":"2025-08-01","current":-9.134632,"twenty":-4.922267,"median":-3.137242,"eighty":-0.969039,"marketCap":14113006},{"date":"2025-08-08","current":-8.476938,"twenty":-5.004125,"median":-3.155299,"eighty":-0.973817,"marketCap":13096869},{"date":"2025-08-15","current":-8.18463,"twenty":-5.134029,"median":-3.19779,"eighty":-0.976803,"marketCap":12645253},{"date":"2025-08-22","current":-7.746168,"twenty":-5.410414,"median":-3.21607,"eighty":-0.982233,"marketCap":11967829},{"date":"2025-08-29","current":-7.600014,"twenty":-5.856236,"median":-3.245278,"eighty":-0.987228,"marketCap":11742021},{"date":"2025-09-05","current":-7.819245,"twenty":-6.049761,"median":-3.325781,"eighty":-0.992223,"marketCap":12080733},{"date":"2025-09-12","current":-7.143282,"twenty":-6.209629,"median":-3.343916,"eighty":-1.006667,"marketCap":11036370},{"date":"2025-09-19","current":-10.354516,"twenty":-6.696876,"median":-3.375088,"eighty":-1.026648,"marketCap":11742021},{"date":"2025-09-26","current":-11.070023,"twenty":-7.035762,"median":-3.443585,"eighty":-1.030557,"marketCap":12553406},{"date":"2025-10-03","current":-11.383325,"twenty":-7.364852,"median":-3.487865,"eighty":-1.042883,"marketCap":12908691},{"date":"2025-10-10","current":-13.054272,"twenty":-7.512322,"median":-3.569805,"eighty":-1.058791,"marketCap":14803545},{"date":"2025-10-17","current":-11.174457,"twenty":-7.59231,"median":-3.644879,"eighty":-1.068565,"marketCap":12671834},{"date":"2025-10-24","current":-11.278891,"twenty":-7.731553,"median":-3.707687,"eighty":-1.123948,"marketCap":12790262},{"date":"2025-10-31","current":-10.75672,"twenty":-7.950784,"median":-3.905854,"eighty":-1.280758,"marketCap":12198121},{"date":"2025-11-07","current":-9.567215,"twenty":-8.038476,"median":-3.996712,"eighty":-1.310622,"marketCap":10849222},{"date":"2025-11-14","current":-8.045608,"twenty":-8.360015,"median":-4.312242,"eighty":-1.376104,"marketCap":9123720},{"date":"2025-11-21","current":-6.109399,"twenty":-8.170015,"median":-4.417419,"eighty":-1.474489,"marketCap":6928059},{"date":"2025-11-28","current":-5.587228,"twenty":-8.111553,"median":-4.501561,"eighty":-1.508371,"marketCap":6335917},{"date":"2025-12-05","current":-25.23826,"twenty":-8.403861,"median":-4.535397,"eighty":-1.515701,"marketCap":28620187},{"date":"2025-12-12","current":-21.591766,"twenty":-8.696169,"median":-4.627772,"eighty":-1.520317,"marketCap":24485063},{"date":"2025-12-19","current":-17.597159,"twenty":-9.06593,"median":-4.711914,"eighty":-1.541633,"marketCap":19955178},{"date":"2025-12-26","current":-13.245735,"twenty":-9.27961,"median":-4.754698,"eighty":-1.546299,"marketCap":15020663},{"date":"2026-01-02","current":-14.777436,"twenty":-10.201257,"median":-4.798393,"eighty":-1.579229,"marketCap":16757612},{"date":"2026-01-09","current":-23.341039,"twenty":-10.662157,"median":-4.922267,"eighty":-1.630419,"marketCap":26468738},{"date":"2026-01-16","current":-21.842963,"twenty":-11.038692,"median":-4.999213,"eighty":-1.702674,"marketCap":24769920},{"date":"2026-01-23","current":-22.02569,"twenty":-11.165081,"median":-5.003554,"eighty":-1.780942,"marketCap":24977133},{"date":"2026-01-30","current":-18.441421,"twenty":-11.278891,"median":-5.035187,"eighty":-1.871075,"marketCap":20912571},{"date":"2026-02-06","current":-17.471559,"twenty":-11.383325,"median":-5.167341,"eighty":-1.959036,"marketCap":19812748}],"updateTime":1770469650331},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PLRZ\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2609151275","title":"BUZZ-U.S. STOCKS ON THE MOVE-SpyGlass, Agomab, Piper Sandler, Molina","url":"https://stock-news.laohu8.com/highlight/detail?id=2609151275","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609151275?lang=en_us&edition=fundamental","pubTime":"2026-02-07 02:45","pubTimestamp":1770403531,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-SpyGlass, Agomab, Piper Sandler, Molina Eikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsl","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260206:nL6N3Z20MX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FTNT","VG","HL","HUBG","MOH","CDE","RIOT","NSC","NEM","EXE","OFRM","PAA","EQT","LEN","HOYY","NWSA","TGTX","AZYY","MGM","DOCS","ROIV","GWW","THAR","NWL","SGP","KBH","UI","PLRZ","PHM","NVR","CG","CNX","COTY","BIIB","PM","AVY","MAXN","MCHP","PIPR","AGMB","UAA"],"gpt_icon":1},{"id":"2609859779","title":"BUZZ-U.S. STOCKS ON THE MOVE-Microchip, Under Armour, Avery Dennison","url":"https://stock-news.laohu8.com/highlight/detail?id=2609859779","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609859779?lang=en_us&edition=fundamental","pubTime":"2026-02-06 23:56","pubTimestamp":1770393385,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Microchip, Under Armour, Avery DennisonEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsle","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260206:nL6N3Z20YC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VG","MAXN","MCHP","UI","MOH","COTY","NSC","PAA","CG","HOYY","AMZZ","NWSA","THAR","09399","AVY","3LMI.UK","HL","CNX","09799","HUBG","RIOT","ROBN","OFRM","GWW","NEM","BIIB","FTNT","07399","HODU","PLRZ","DOCS","TGTX","ROIV","PM","CDE","NWL","AMZD","EQT","UAA","MGM","EXE"],"gpt_icon":1},{"id":"2609962715","title":"BRIEF-Clearmind Medicine Enters Development Agreement For Intranasal Formulation Of Proprietary Nonhallucinogenic Neuroplastogen MEAI","url":"https://stock-news.laohu8.com/highlight/detail?id=2609962715","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609962715?lang=en_us&edition=fundamental","pubTime":"2026-02-06 21:30","pubTimestamp":1770384643,"startTime":"0","endTime":"0","summary":"BRIEF-Clearmind Medicine Enters Development Agreement For Intranasal Formulation Of Proprietary Nonhallucinogenic Neuroplastogen MEAIFeb 6 (Reuters) - Clearmind Medicine Inc CMND.O:CLEARMIND MEDICINE ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260206:nFWN3Z20V9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CMND","PLRZ"],"gpt_icon":0},{"id":"2609596155","title":"BUZZ-Polyrizon jumps as it teams up with Clearmind for intranasal drug delivery","url":"https://stock-news.laohu8.com/highlight/detail?id=2609596155","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609596155?lang=en_us&edition=fundamental","pubTime":"2026-02-06 21:25","pubTimestamp":1770384335,"startTime":"0","endTime":"0","summary":"BUZZ-Polyrizon jumps as it teams up with Clearmind for intranasal drug delivery** Shares of drug developer Polyrizon PLRZ.O rise 12.6% to $14.00 premarket ** Co says it will develop an intranasal version of Clearmind’s CMND.O experimental MEAI therapy, being studied for addiction-related brain disorders** CNMD's shares were up 20% at $1.7 premarket** CNMD's MEAI is designed to reshape neural pathways without hallucinations; intranasal delivery may help faster absorption and bypass the liver, per co** Co says its gel-like nasal platform aims to keep drugs longer in the nose and improve targeted delivery** PLRZ shares down over 99%, CNMD down ~41% in 2025  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260206:nL4N3Z21E3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","PLRZ","CMND"],"gpt_icon":0},{"id":"2609953545","title":"Clearmind Medicine Enters Into Development Agreement to Advance Intranasal Formulation for Its Proprietary Non-Hallucinogenic Neuroplastogen Meai","url":"https://stock-news.laohu8.com/highlight/detail?id=2609953545","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609953545?lang=en_us&edition=fundamental","pubTime":"2026-02-06 20:55","pubTimestamp":1770382530,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260206:nFWN3Z20V9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PLRZ","BK4007","CMND"],"gpt_icon":0},{"id":"2609259539","title":"Polyrizon Partners with Clearmind to Develop Intranasal MEAI Formulation","url":"https://stock-news.laohu8.com/highlight/detail?id=2609259539","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609259539?lang=en_us&edition=fundamental","pubTime":"2026-02-06 20:55","pubTimestamp":1770382510,"startTime":"0","endTime":"0","summary":"Polyrizon Ltd., a pre-clinical-stage biotechnology company, has entered into a development agreement with Clearmind Medicine Inc., a clinical-stage biopharmaceutical firm. The collaboration focuses on developing a proprietary intranasal formulation of MEAI, Clearmind's next-generation, non-hallucinogenic neuroplastogen drug candidate aimed at treating addiction-related and other central nervous system conditions. Polyrizon will leverage its advanced intranasal delivery platform to enhance the clinical development of MEAI, offering targeted delivery and potentially faster absorption. The partnership is expected to support Clearmind's future clinical programs and highlights Polyrizon's expertise in specialized intranasal drug delivery solutions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260206:nNDL95mddZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMND","LU2210150020.SGD","IE00B64PRP62.GBP","IE00BKPKM429.USD","BK4112","BK4007","SG9999014039.USD","SG9999014021.USD","IE00BGHQF748.EUR","NDAQ","LU2210149790.SGD","BK4585","IE00B3QW5Z07.USD","PLRZ","SG9999014005.SGD","SG9999014013.SGD","LU0314104364.USD","BK4588","LU2095319765.USD"],"gpt_icon":0},{"id":"2609595351","title":"Polyrizon Signs an Agreement to Develop Intranasal Proprietary Non-Hallucinogenic Neuroplastogen Formulation","url":"https://stock-news.laohu8.com/highlight/detail?id=2609595351","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609595351?lang=en_us&edition=fundamental","pubTime":"2026-02-06 20:55","pubTimestamp":1770382500,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260206:nTUA32DWG8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CMND","BK4007","PLRZ"],"gpt_icon":0},{"id":"2608696793","title":"Polyrizon intends to acquire 51% stake in Arrow Aviation for NIS 18M","url":"https://stock-news.laohu8.com/highlight/detail?id=2608696793","media":"TIPRANKS","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608696793?lang=en_us&edition=fundamental","pubTime":"2026-02-04 20:15","pubTimestamp":1770207320,"startTime":"0","endTime":"0","summary":"Polyrizon (PLRZ) announced the signing of a non-binding Memorandum of Understanding with Arrow Aviation, a global private aviation company. Under t...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/polyrizon-intends-to-acquire-51-stake-in-arrow-aviation-for-nis-18m-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/polyrizon-intends-to-acquire-51-stake-in-arrow-aviation-for-nis-18m-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4211","PLRZ","AROW"],"gpt_icon":0},{"id":"2608667233","title":"Polyrizon to Acquire 51% Stake in Arrow Aviation","url":"https://stock-news.laohu8.com/highlight/detail?id=2608667233","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608667233?lang=en_us&edition=fundamental","pubTime":"2026-02-04 20:12","pubTimestamp":1770207135,"startTime":"0","endTime":"0","summary":"Polyrizon Ltd. has signed a non-binding Memorandum of Understanding with Arrow Aviation Ltd., under which Polyrizon intends to acquire a 51% stake in Arrow Aviation for approximately $5.8 million in cash. The deal includes ancillary arrangements such as the transfer of a Hawker 800 aircraft valued at $3.5 million to Arrow Aviation by a third party, in exchange for a convertible note issued by Polyrizon. Additionally, existing Arrow Aviation shareholders will forgive outstanding debts in return for convertible notes from Polyrizon, allowing Arrow Aviation to emerge debt-free after the closing. The agreement outlines mutual call and put options on the remaining 49% of Arrow Aviation shares, exercisable after two years and based on agreed financial metrics, which could result in Polyrizon ultimately acquiring 100% of Arrow Aviation. Arrow Aviation currently reports annual unaudited revenues of approximately $19 million and adjusted EBITDA of about $3 million. The signing of a definitive a","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260204:nNDL2CfN7c:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","IE00BKPKM429.USD","SG9999014005.SGD","SG9999014013.SGD","SG9999014021.USD","PLRZ","LU2210149790.SGD","LU2210150020.SGD","BK4585","IE00BGHQF748.EUR","BK4588","LU2095319765.USD","BK4112","SG9999014039.USD","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","LU0314104364.USD"],"gpt_icon":0},{"id":"2608667163","title":"Polyrizon Ltd - to Buy 51% Stake in Arrow Aviation for $5.8 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2608667163","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608667163?lang=en_us&edition=fundamental","pubTime":"2026-02-04 20:12","pubTimestamp":1770207120,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260204:nTUA8YD90G:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PLRZ"],"gpt_icon":0},{"id":"2605974414","title":"Polyrizon initiates key usability study program for NASARIX","url":"https://stock-news.laohu8.com/highlight/detail?id=2605974414","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605974414?lang=en_us&edition=fundamental","pubTime":"2026-01-22 22:31","pubTimestamp":1769092283,"startTime":"0","endTime":"0","summary":"Polyrizon (PLRZ) announced the initiation of a key usability study program for its lead product candidate, NASARIX, an intranasal allergy blocker d...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/polyrizon-initiates-key-usability-study-program-for-nasarix-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/polyrizon-initiates-key-usability-study-program-for-nasarix-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PLRZ"],"gpt_icon":0},{"id":"2605492701","title":"Polyrizon Advances Regulatory Path With Initiation of Usability Study Program for Nasarix™ Allergy Blocker","url":"https://stock-news.laohu8.com/highlight/detail?id=2605492701","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605492701?lang=en_us&edition=fundamental","pubTime":"2026-01-22 22:25","pubTimestamp":1769091900,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260122:nTUA81KWXR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PLRZ"],"gpt_icon":0},{"id":"2603368761","title":"Polyrizon announces board authorized exploration of investment opportunities","url":"https://stock-news.laohu8.com/highlight/detail?id=2603368761","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603368761?lang=en_us&edition=fundamental","pubTime":"2026-01-13 21:55","pubTimestamp":1768312515,"startTime":"0","endTime":"0","summary":"Polyrizon (PLRZ) recently announced that its Board of Directors has authorized the exploration of strategic investment opportunities in select reve...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/polyrizon-announces-board-authorized-exploration-of-investment-opportunities-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/polyrizon-announces-board-authorized-exploration-of-investment-opportunities-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PLRZ"],"gpt_icon":0},{"id":"2603682777","title":"BRIEF-Polyrizon Ltd To Explore Revenue-Generating Investment Opportunities In High-Growth Sectors","url":"https://stock-news.laohu8.com/highlight/detail?id=2603682777","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603682777?lang=en_us&edition=fundamental","pubTime":"2026-01-13 21:43","pubTimestamp":1768311783,"startTime":"0","endTime":"0","summary":"BRIEF-Polyrizon Ltd To Explore Revenue-Generating Investment Opportunities In High-Growth SectorsJan 13 (Reuters) - Polyrizon Ltd PLRZ.O:POLYRIZON LTD: TO EXPLORE REVENUE-GENERATING INVESTMENT OPPORTU","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nFWN3YE13D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLRZ"],"gpt_icon":0},{"id":"2603822316","title":"Polyrizon Ltd: Board Has Approved Pursing Selective Investments That Are Expected to Generate Near-Term Revenues","url":"https://stock-news.laohu8.com/highlight/detail?id=2603822316","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603822316?lang=en_us&edition=fundamental","pubTime":"2026-01-13 21:40","pubTimestamp":1768311610,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nFWN3YE13D:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PLRZ"],"gpt_icon":0},{"id":"2603682298","title":"Polyrizon - Focusing Its Initial Efforts on Operating Companies in High-Potential Sectors, Including Defense, Aviation, and AI","url":"https://stock-news.laohu8.com/highlight/detail?id=2603682298","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603682298?lang=en_us&edition=fundamental","pubTime":"2026-01-13 21:40","pubTimestamp":1768311610,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nFWN3YE13D:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PLRZ"],"gpt_icon":0},{"id":"2603682239","title":"Polyrizon Ltd: to Explore Revenue-Generating Investment Opportunities in High-Growth Sectors","url":"https://stock-news.laohu8.com/highlight/detail?id=2603682239","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603682239?lang=en_us&edition=fundamental","pubTime":"2026-01-13 21:40","pubTimestamp":1768311610,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nFWN3YE13D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PLRZ"],"gpt_icon":0},{"id":"2603682142","title":"Polyrizon Ltd. Announces Plans to Explore Revenue-Generating Investments in Defense, Aviation, and AI Sectors While Advancing Core Intranasal Medical Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2603682142","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603682142?lang=en_us&edition=fundamental","pubTime":"2026-01-13 21:39","pubTimestamp":1768311550,"startTime":"0","endTime":"0","summary":"Polyrizon Ltd. Announces Plans to Explore Revenue-Generating Investments in Defense, Aviation, and AI Sectors While Advancing Core Intranasal Medical Pipeline. Polyrizon Ltd. has announced a strategic initiative to explore selective investments in revenue-generating assets, focusing on companies operating in high-potential sectors such as defense, aviation, and artificial intelligence. The company aims to utilize its strong cash position and debt-free balance sheet to generate near-term revenues, enhance financial stability, and create additional shareholder value. While pursuing these opportunities, Polyrizon will continue to prioritize the advancement of its core intranasal medical device pipeline, including ongoing product development, preclinical and clinical studies, and regulatory progress for products such as PL-14, PL-16, and the Trap & Target platform.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nNDL5lpmF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLRZ","LU2095319765.USD","BK4585","LU0314104364.USD","IE00BKPKM429.USD","SG9999014005.SGD","BK4588","SG9999014013.SGD","SG9999014021.USD","IE00B3QW5Z07.USD","NDAQ","BK4112","LU2210150020.SGD","LU2210149790.SGD","IE00BGHQF748.EUR","SG9999014039.USD","IE00B64PRP62.GBP"],"gpt_icon":0},{"id":"2601955398","title":"BRIEF-Polyrizon Expects Nasarix Introduction Aligned With Clinical Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2601955398","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601955398?lang=en_us&edition=fundamental","pubTime":"2026-01-08 22:39","pubTimestamp":1767883173,"startTime":"0","endTime":"0","summary":"BRIEF-Polyrizon Expects Nasarix Introduction Aligned With Clinical ProgressJan 8 (Reuters) - Polyrizon Ltd PLRZ.O:POLYRIZON LTD - EXPECTS NASARIX INTRODUCTION ALIGNED WITH CLINICAL PROGRESSSource text: ID:nGNX9G0DclFurther company coverage: PLRZ.O ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nFWN3Y90NI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLRZ"],"gpt_icon":0},{"id":"2601588265","title":"Polyrizon's PL-14 Outperforms Standard Nasal Barrier in Blocking Allergens","url":"https://stock-news.laohu8.com/highlight/detail?id=2601588265","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601588265?lang=en_us&edition=fundamental","pubTime":"2026-01-05 22:07","pubTimestamp":1767622031,"startTime":"0","endTime":"0","summary":"Polyrizon Ltd., a pre-clinical-stage biotechnology company, announced positive results from a new in-vitro pre-clinical study evaluating its PL-14 Allergy Blocker formulation. The study assessed PL-14's ability to block the transfer of Der p 1, a major house dust mite allergen, in a validated laboratory model simulating nasal tissue. Results showed that PL-14 significantly outperformed hydroxypropyl methylcellulose , a standard nasal barrier comparator, by maintaining much lower allergen permeation at all tested time points. PL-14 achieved a maximum mean allergen level of approximately 141.2 ng at 4 hours, compared to HPMC's 5201.2 ng at 24 hours. Polyrizon plans to use these findings to support future clinical studies aimed at establishing PL-14's regulatory pathway and clinical benefits for allergy prevention. The company did not specify if or when these results will be presented at a scientific meeting.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nNDLc0vLNy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","BK4585","LU2095319765.USD","LU2210150020.SGD","LU0314104364.USD","BK4588","LU2210149790.SGD","IE00BKPKM429.USD","SG9999014013.SGD","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","SG9999014039.USD","BK4112","PLRZ","IE00BGHQF748.EUR","SG9999014005.SGD","SG9999014021.USD"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":61,"code":"91000000","status":"200"}]}}